Bio-Thera Solutions, Ltd. (688177.SS)
- Previous Close
26.73 - Open
27.57 - Bid 27.70 x --
- Ask 27.72 x --
- Day's Range
27.04 - 28.10 - 52 Week Range
24.03 - 47.46 - Volume
1,831,632 - Avg. Volume
1,981,451 - Market Cap (intraday)
11.478B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.90 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions in China and internationally. It offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer; and BAT1806 for the treatment of rheumatoid arthritis, systemicjuvenile idiopathic arthritis, and cytokine release syndrome. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration (wAMD) and Phase II clinical trial for the treatment for diabetic macular edema (DME); and BAT2022 to treat respiratory infectious diseases. Bio-Thera Solutions, Ltd. was founded in 2003 and is headquartered in Guangzhou, China.
www.bio-thera.comRecent News: 688177.SS
Performance Overview: 688177.SS
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688177.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688177.SS
Valuation Measures
Market Cap
11.48B
Enterprise Value
11.61B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.09
Price/Book (mrq)
10.49
Enterprise Value/Revenue
16.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.13%
Return on Assets (ttm)
-11.26%
Return on Equity (ttm)
-29.00%
Revenue (ttm)
711.46M
Net Income Avi to Common (ttm)
-370.9M
Diluted EPS (ttm)
-0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
462.53M
Total Debt/Equity (mrq)
54.20%
Levered Free Cash Flow (ttm)
-506.86M
Company Insights: 688177.SS
688177.SS does not have Company Insights